JP2011157386A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157386A5
JP2011157386A5 JP2011084716A JP2011084716A JP2011157386A5 JP 2011157386 A5 JP2011157386 A5 JP 2011157386A5 JP 2011084716 A JP2011084716 A JP 2011084716A JP 2011084716 A JP2011084716 A JP 2011084716A JP 2011157386 A5 JP2011157386 A5 JP 2011157386A5
Authority
JP
Japan
Prior art keywords
estradiol
water
particles
cholesterol
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011084716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157386A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157386A publication Critical patent/JP2011157386A/ja
Publication of JP2011157386A5 publication Critical patent/JP2011157386A5/ja
Pending legal-status Critical Current

Links

JP2011084716A 2003-06-13 2011-04-06 避妊及びホルモン補充療法用の調合製剤 Pending JP2011157386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47793903P 2003-06-13 2003-06-13
US60/477,939 2003-06-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006516535A Division JP4956185B2 (ja) 2003-06-13 2004-06-10 避妊及びホルモン補充療法用の調合製剤

Publications (2)

Publication Number Publication Date
JP2011157386A JP2011157386A (ja) 2011-08-18
JP2011157386A5 true JP2011157386A5 (enExample) 2012-03-22

Family

ID=33551788

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516535A Expired - Fee Related JP4956185B2 (ja) 2003-06-13 2004-06-10 避妊及びホルモン補充療法用の調合製剤
JP2011084716A Pending JP2011157386A (ja) 2003-06-13 2011-04-06 避妊及びホルモン補充療法用の調合製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006516535A Expired - Fee Related JP4956185B2 (ja) 2003-06-13 2004-06-10 避妊及びホルモン補充療法用の調合製剤

Country Status (23)

Country Link
US (2) US7589082B2 (enExample)
EP (3) EP1663161B1 (enExample)
JP (2) JP4956185B2 (enExample)
CN (2) CN100594907C (enExample)
AT (1) ATE454885T1 (enExample)
AU (1) AU2004246870B2 (enExample)
BR (1) BRPI0411335A (enExample)
CA (2) CA2528545C (enExample)
CY (1) CY1109967T1 (enExample)
DE (1) DE602004025156D1 (enExample)
DK (3) DK1844765T3 (enExample)
EA (3) EA012783B1 (enExample)
ES (3) ES2537551T3 (enExample)
HU (1) HUE025147T2 (enExample)
IL (2) IL172466A (enExample)
MX (1) MX2008014654A (enExample)
NO (1) NO341540B1 (enExample)
OA (1) OA13307A (enExample)
PL (3) PL1820494T3 (enExample)
PT (3) PT1663161E (enExample)
SI (3) SI1844765T1 (enExample)
TW (1) TWI336623B (enExample)
WO (1) WO2004110408A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589082B2 (en) 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy
CN102056611A (zh) * 2008-04-14 2011-05-11 Posi维森纳里解决方案有限责任公司 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2012129305A1 (en) * 2011-03-23 2012-09-27 Pop Test Cortisol Llc Combination therapy
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
ITUB20153652A1 (it) * 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180123165A (ko) * 2016-04-01 2018-11-14 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
PL3272732T3 (pl) 2016-07-19 2020-03-31 Evonik Degussa Gmbh Sposób alkoksykarbonylowania etylenowo nienasyconych związków za pomocą ligandów monofosfinowych
KR102954589B1 (ko) * 2018-11-29 2026-04-20 인시그나 인크. 불임제로서의 에스트라디올 벤조에이트
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP3954364A1 (en) 2020-08-14 2022-02-16 Chemo Research, S.L. New modified release oral contraceptive composition
US12691126B2 (en) 2022-05-26 2026-07-28 Insigna Inc. Non-surgical prevention of unpleasant odor in meats and aggressive or sexual behavior in male ruminants
US11938140B2 (en) 2022-05-26 2024-03-26 Insigna Inc. Non-surgical prevention of boar taint and aggressive behavior
US12691125B2 (en) 2022-05-26 2026-07-28 Insigna, Inc. Prevention of estrus in sow and ruminants

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
GB1367608A (en) * 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4180560A (en) * 1976-10-26 1979-12-25 Syntex Corporation Inert core implant pellet
JPS5799562A (en) 1980-12-12 1982-06-21 Nippon Shinyaku Co Ltd Preparation of microcrystal
US5023092A (en) 1988-06-16 1991-06-11 Ici Americas Inc. Mannitol having gamma sorbitol polymorph
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
DE4130173A1 (de) 1991-09-11 1993-03-18 Bayer Ag Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
SE9301171D0 (sv) * 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
FR2747042B1 (fr) 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
US5762956A (en) * 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
EP0888790A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Drug particle delivery device
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
EP1591121B1 (en) * 2000-12-14 2009-06-24 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US7589082B2 (en) 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy

Similar Documents

Publication Publication Date Title
CN102827153B (zh) 阿齐沙坦的晶型及其制备方法
JP2012521377A5 (enExample)
JP2008533007A5 (enExample)
JP2013529665A5 (enExample)
RU2011108220A (ru) Кристаллические микрочастицы действующего вещества, способ их изготовления и их применение в лекарственных средствах
RU2016142819A (ru) Твердая композиция, содержащая аморфный софосбувир
JP2018504445A5 (enExample)
JP2014524442A5 (enExample)
JP2013530686A5 (enExample)
JP2008512426A5 (enExample)
JP2013018787A5 (enExample)
JP2014097964A5 (enExample)
JP2015523546A5 (enExample)
JP2013535505A5 (enExample)
FI3258919T4 (fi) Nasaalinen jauheformulaatio hypoglykemian hoitoon
HRP20231201T1 (hr) Kristalni metiltionij klorid hidrati
JP2012004269A5 (enExample)
JP2014125461A5 (enExample)
JP2013509360A5 (enExample)
JP2014503593A5 (enExample)
JP2009179634A5 (enExample)
JP2013538849A5 (enExample)
JP2017520564A5 (enExample)
JP2022526675A5 (enExample)
JP2011500811A5 (enExample)